Recruiting Migraine Studies in Huntsville
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits....
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Mig...
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will la...
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other sy...
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, o...
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to...
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is t...
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is t...
About Migraine Clinical Trials in Huntsville
Migraine is a neurological condition characterized by intense, debilitating headaches often accompanied by nausea, light sensitivity, and visual disturbances. It affects about 1 billion people globally and is a leading cause of disability. Treatments include preventive medications, acute therapies, and newer CGRP-targeting drugs.
There are currently 8 migraine clinical trials recruiting participants in Huntsville, TEXAS. These studies are seeking a combined 5,637 participants. Research is being sponsored by Eli Lilly and Company, AbbVie. Clinical trial participation is free and participants receive study-related medical care at no cost.
Migraine Clinical Trials in Huntsville — FAQ
Are there migraine clinical trials in Huntsville?
Yes, there are 8 migraine clinical trials currently recruiting in Huntsville, TEXAS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Huntsville?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Huntsville research site will contact you about next steps.
Are clinical trials in Huntsville free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Huntsville studies also compensate for your time and travel.
What migraine treatments are being tested?
The 8 active trials in Huntsville are testing new therapies including novel drugs, biologics, and treatment approaches for migraine.
Data updated March 2, 2026 from ClinicalTrials.gov